|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Thoracic and Cardiovascular Surgery (Drs. Tsuchida, Yamato, Aoki, Watanabe, and Hayashi), the Department of Radiology (Dr. Koizumi), and the Department of Surgical Pathology (Dr. Emura), Niigata University School of Medicine, Niigata, Japan.
Correspondence to: Masanori Tsuchida, MD, Department of Thoracic and Cardiovascular Surgery, Niigata University School of Medicine, 1757 Asahimachi-dori 951-8510 Japan
| Abstract |
|---|
|
|
|---|
Study objectives: To localize and resect nonpalpable and invisible small pulmonary lesions, a new marking technique that we call "agar marking" was developed.
Methods and patients: Powdered agar was dissolved in distilled water at a concentration of 5% and kept at > 50°C to maintain its liquid form. Agar was injected through an 18-gauge needle and placed near the target lesion with CT. After animal experiments, agar marking was applied to the nine patients who had lesions < 20 mm in diameter and lesions with GGO. The mean diameter of these lesions was 11 mm, with a mean depth of 19 mm from the pleural surface on CT.
Results: Agar could be detected as a hard nodule by manual palpation, and the lesion was resected during thoracotomy in all cases. There were no complications associated with the agar injection, aside from one case of slight pneumothorax.
Conclusions: Agar marking may represent a feasible alternative technique for localizing nonpalpable occult lesions located away from the pleural surface.
Key Words: agar marking CT ground-glass opacity occult lesion peripheral pulmonary lesion
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Experimental Study
Before clinical application, we performed an animal study
(unpublished study; September 10 to September 15, 1997) and an ex
vivo study (unpublished study; September 20, 1997) using the human
lung. Five beagle dogs weighing 10 to 15 kg were anesthetized, agar was
injected percutaneously through an 18-gauge needle under
roentgenographic fluoroscopy, and localization of the agar was tested.
All animals received humane care in accordance with the guidelines for
animal experimentation of Niigata University. In addition, agar was
injected into three resected human lungs, and manual palpation and
microscopic evaluation was performed.
Patients
Preoperative agar marking was performed in nine patients whose
lesions were thought to be difficult to identify. All patients
underwent CT for lung cancer screening. The indications for agar
marking were as follows: GGO lesions < 20 mm in diameter and lesions
located deeper than 10 mm from the pleural surface.
Agar Injection
All of the patients agreed to undergo this procedure and gave
their informed consent. All procedures were approved by the local
institutional committee. Each patient was positioned on the CT table in
a suitable position. Figure 1
demonstrates the CT-guided agar injection. The GGO lesion is 8 mm in
size and is located at a depth of 20 mm from the pleural surface (Fig 1
Top, A). With CT guidance, an 18-gauge needle was placed
percutaneously through the chest wall into the lung parenchyma (Fig 1
Center, B). The needle tip was placed so that the agar was
located a little bit deeper than the target lesion. After confirming
that the needle was placed in the appropriate position with no blood
backflow, warm agar was mixed with contrast media (1-to-10 dilution),
and 1 mL of the mixture was injected before the agar became a hard gel
(Fig 1
, Bottom, C). The presence of the agar nodule was
confirmed by consecutive CT scan, and the patient was transferred to
the operating room.
|
|
| Results |
|---|
|
|
|---|
As of August 1997, agar has been used in patients with GGO lesions that are < 20 mm in size and located deeper than 10 mm below the pleural surface. The characteristics of nine patients are summarized in Table 1 . The maximum diameter of the tumor ranged from 8 to 17 mm on the CT scans. The distance from the pleural surface to the tumor ranged from 10 to 32 mm. All lesions had GGO density, and two of them had a small high-density area in the middle of the tumor. In all cases, agar was placed successfully near the target lesion but not within the lesion. The average time needed to complete the marking procedure was 1 h. In all cases, agar could be detected as a hard nodule, whereas cloudy lesions were nonpalpable. Occult lesions were resected by wedge resection in seven cases, and by segmentectomy in two cases in which the tumor was located too centrally to resect by wedge resection. The confirmed histology showed bronchioloalveolar adenocarcinoma without active fibrotic proliferation in eight cases and atypical adenomatous hyperplasia in one case. The histologic diagnosis using paraffin-embedded sections completely coincided with the intraoperative frozen-section diagnosis. To exclude the possibility of tumor dissemination associated with this technique, intraoperative pleural lavage was performed, and no tumor cells were identified.
|
| Discussion |
|---|
|
|
|---|
Several methods of localization have been reported4 5 6 7 8 9 10 11 12 13 for resecting small nodules under thoracoscopy. However, each technique has some limitations for deep and nonpalpable lesions. The preoperative injection of methylene blue4 7 8 does not indicate the depth of the lesions, and it might be difficult to determine the resectional line. Ultrasound techniques require the lesions to be somewhat hard, which is not common in GGO lesions. The hook-wire technique8 9 is also of limited use for deep lesions because the hook-wire sometimes dislodges from its initially inserted position. Nomori and Horio11 have reported a long-lasting point marker called colored collagen. This marker stays in place without diffusion for a long time and can be visualized under thoracoscopy. Kobayashi et al13 have reported the use of CT-guided bronchoscopic barium marking for resection of invisible lesions. It is not clear, however, that these two techniques would be useful for deep lesions. All of these techniques were developed based on either direct or fluoroscopically assisted visualization.
On the other hand, agar marking depends on "touch feeling" by a surgeon's hands and provides a palpable marker. Agar is a gelatin-like product made from certain seaweeds that is used for solidifying culture media and as a thickening agent for foods. Because the metabolism of agar within lung tissue has not been tested, it should be resected completely, as with other types of markers. Compared with other marking techniques, agar marking is especially useful for nonpalpable lesions located away from the pleural surface. The surgeon can palpate the agar marker placed near the lesions and determine with confidence how deep the resectional line should be. Even when the lesion is located in the central part of the lung near the hilum, making an anatomic resection such as a segmentectomy necessary, an agar marker provides a certain localization of the tumor and an appropriate resectional line. Agar is cheap (< $1 per case), and it can be injected easily because of its liquid form. Furthermore, agar is easily cut and does not interrupt a pathologic examination. The only change brought about by an agar injection is an enlargement of the alveolus of the injected site. The disadvantage of this technique, however, is the need for thoracotomy to palpate the marker. Because the marker contains contrast media, however, it is possible to resect the lesion under roentgenographic fluoroscopy without thoracotomy. As experience grows with this technique, it may be possible to complete the procedure under thoracoscopy alone for the next step.
No complications have been observed in association with agar injection, aside from one case of slight pneumothorax. In addition, no cancer dissemination has occurred, as confirmed by cytologic examination of pleural lavage fluid. Because intravessel injection with distal embolization of the agar is a possible serious complication associated with this technique, it is important to place the tip of the needle away from vessels and to make sure there is no blood backflow. Therefore, this procedure is not without risk, and a large series is needed to prove its safety. In the present study, we simultaneously required both the CT and the operating room to resect the agar marker as soon as possible. Because this agar marker remained in place for > 2 weeks in the animal studies, it is possible that this procedure can be performed some days prior to the operation.
In conclusion, agar marking is a simple and useful method for localizing and resecting occult pulmonary lesions with GGO. Agar marking may represent a feasible alternative technique for the localization of the following lesions: (1) lesions located some depth from the pleural surface; and (2) nonpalpable and invisible lesions with GGO.
| Acknowledgements |
|---|
| Footnotes |
|---|
Received for publication July 17, 1998. Accepted for publication January 25, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K.-i. Watanabe, H. Nomori, T. Ohtsuka, M. Kaji, T. Naruke, and K. Suemasu Usefulness and complications of computed tomography-guided lipiodol marking for fluoroscopy-assisted thoracoscopic resection of small pulmonary nodules: Experience with 174 nodules. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 320 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mattioli, F. D'Ovidio, N. Daddi, L. Ferruzzi, V. Pilotti, A. Ruffato, R. Bolzani, and G. Gavelli Transthoracic Endosonography for the Intraoperative Localization of Lung Nodules Ann. Thorac. Surg., February 1, 2005; 79(2): 443 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sugi, Y. Kaneda, K. Hirasawa, and N. Kunitani Radioisotope Marking Under CT Guidance and Localization Using a Handheld Gamma Probe for Small or Indistinct Pulmonary Lesions Chest, July 1, 2003; 124(1): 155 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Takashima, S. Sone, F. Li, Y. Maruyama, M. Hasegawa, T. Matsushita, F. Takayama, and M. Kadoya Small Solitary Pulmonary Nodules (<=1 cm) Detected at Population-Based CT Screening for Lung Cancer: Reliable High-Resolution CT Features of Benign Lesions Am. J. Roentgenol., April 1, 2003; 180(4): 955 - 964. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Burdine, L. D. Joyce, M. B. Plunkett, S. Inampudi, M. G. Kaye, and D. H. Dunn Feasibility and Value of Video-Assisted Thoracoscopic Surgery Wedge Excision of Small Pulmonary Nodules in Patients With Malignancy Chest, October 1, 2002; 122(4): 1467 - 1470. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Andrea, C. Paolo, S. Ascanelli, S. Davide, and P. Enzo Significance of a single pulmonary nodule in patients with previous history of malignancy Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1101 - 1105. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yamato, M. Tsuchida, T. Watanabe, T. Aoki, N. Koizumi, H. Umezu, and J.-i. Hayashi Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung Ann. Thorac. Surg., March 1, 2001; 71(3): 971 - 974. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |